Rigel Pharmaceuticals Inc (RIGL)
R&D Expense Growth
19.57%
Quarterly · Period ending:
RIGL R&D Expense Growth
Latest reported19.57%period ending
Latest reported19.57%period ending
RIGL Quarterly R&D Growth (QoQ) (0.00% → 19.57%)
Latest values, visible window
High-resolution chart · PNG
RIGL r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 19.5701% | |
| 9.2747% | |
| 45.3148% | |
| 7.7994% | |
| -19.1441% | |
| 49.7869% | |
| -8.8968% | |
| 11.5884% | |
| -8.0651% | |
| 89.14% | |
| -50.7954% | |
| 35.6873% | |
| -52.701% | |
| -34.3378% | |
| 4.7661% | |
| -0.684% | |
| -4.569% | |
| 16.3109% | |
| -27.3005% | |
| 8.8832% | |
| -0.1129% | |
| 11.1507% | |
| 3.6849% | |
| 2.7156% | |
| -11.9822% | |
| 13.3502% | |
| -1.4935% | |
| 9.3528% | |
| 20.7964% | |
| -20.4692% | |
| 24.0606% | |
| 2.7785% | |
| -3.9584% | |
| -2.7593% | |
| 6.9671% | |
| -6.2131% | |
| -6.8843% | |
| 6.3779% | |
| -28.0564% | |
| -7.425% | |
| -3.8794% | |
| 9.7205% | |
| 6.8512% | |
| 2.9351% | |
| -4.095% | |
| 7.4523% | |
| -9.5226% | |
| -19.4986% | |
| 18.9341% | |
| -6.5222% | |
| 2.6858% | |
| -9.3797% | |
| -4.5385% | |
| 2.7879% | |
| -2.0906% | |
| -3.5271% | |
| 16.8677% | |
| -9.6624% | |
| 14.4548% | |
| 1.2099% | |
| 13.2596% | |
| 9.7979% | |
| -16.0791% | |
| -2.5037% | |
| -3.5007% | |
| -13.6307% | |
| -4.3022% | |
| -15.4962% | |
| 1.6709% | |
| -13.6047% | |
| -9.0612% | |
| 9.9099% | |
| 31.4339% | |
| -1.5483% | |
| 42.8571% | |
| -10.5707% | |
| 8.4959% | |
| 5.6059% | |
| 6.7758% | |
| 6.3991% | |
| -10.2372% | |
| 9.9313% | |
| -2.1498% | |
| -0.9488% | |
| 23.5747% | |
| -9.1257% | |
| -7.3195% | |
| 17.7316% | |
| -3.6429% | |
| 0.24% | |
| 6.1607% | |
| 2.7201% | |
| 6.8731% | |
| 4.6086% | |
| -17.6789% | |
| -3.6632% | |
| 19.5719% | |
| 13.1532% | |
| 3.3252% | |
| -1.7753% |